Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine strategy aims to shield lymphoma patients from deadly infections

NCT ID NCT04214444

Prevention Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a two-step vaccine approach to prevent pneumococcal infections in 26 adults with diffuse large B-cell lymphoma who were receiving chemotherapy with rituximab. The vaccines, Prevenar and Pneumovax, were given in a prime-boost sequence to boost immune protection. The goal was to see if this strategy could improve antibody responses and reduce infection risk in these vulnerable patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

26 people

The number who actually took part.

Started

Jul 2020

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * De novo Diffuse Large B-Cell Lymphoma diagnostic (according 2016 World Health Organization (WHO) classification) * Treatment decision by immunochemotherapy (R-CHOP) * Age over 18 years old * Negative pregnancy test at inclusion * Active contraception at inclusion * Free and informed consent procedure at inclusion * Affiliation of the social security system Exclusion Criteria: * Patient with prior treatment by immunotherapy or chemotherapy * Patient with prior treatment by debulking chemotherapy (COP) * Patient with prior treatment by high-dose of corticosteroids * Patients with an autoimmune disease * Patients with a diffuse large B-cell lymphoma from transformation (follicular lymphoma, chronic lymphoid leukemia) * Immunosuppressed patient with : asplenia, hereditary immunodeficiency disorder, infection by HIV, hepatitis B or C viruses, transplanted patient, hematopoietic stem cell transplantation, nephrotic syndrome, meningeal breach, cochlear implants. * Patients vaccinated in the last month before inclusion * Patients with prior transfusion of blood-products or immunoglobulins in the last three months before inclusion * Patient with bleeding disorders or thrombopenia contraindicating intramuscular injection * Patient with prior pneumococcal documented infection * Patient with current pregnancy and/or breastfeeding * Patient under curatorship or guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoma, large B-cell, diffuse are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, large B-cell, diffuse Pneumococcal infections

Contacts and locations

Locations

  • GYAN

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.